Molecular diagnosis of retinoblastoma by circulating tumor DNA analysis.


Journal

European journal of cancer (Oxford, England : 1990)
ISSN: 1879-0852
Titre abrégé: Eur J Cancer
Pays: England
ID NLM: 9005373

Informations de publication

Date de publication:
09 2021
Historique:
received: 18 03 2021
revised: 11 05 2021
accepted: 27 05 2021
pubmed: 24 7 2021
medline: 18 11 2021
entrez: 23 7 2021
Statut: ppublish

Résumé

The analysis of circulating tumor DNA (ctDNA), a fraction of total cell-free DNA (cfDNA), might be of special interest in retinoblastoma patients. Because the accessibility to tumor tissue is very limited in these patients, either for histopathological diagnosis of suspicious intraocular masses (biopsies are proscribed) or for somatic RB1 studies and genetic counseling (due to current successful conservative approaches), we aim to validate the detection of ctDNA in plasma of non-hereditary retinoblastoma patients by molecular analysis of RB1 gene. In a cohort of 19 intraocular unilateral non-hereditary retinoblastoma patients for whom a plasma sample was available at diagnosis, we performed high-deep next-generation sequencing (NGS) of RB1 in cfDNA. Two different bioinformatics/statistics approaches were applied depending on whether the somatic RB1 status was available or not. Median plasma sample volume was 600 μL [100-1000]; median cfDNA plasma concentration was 119 [38-1980] and 27 [11-653] ng/mL at diagnosis and after complete remission, respectively. In the subgroup of patients with known somatic RB1 alterations (n = 11), seven of nine somatic mutations were detected (median allele fraction: 6.7%). In patients without identified somatic RB1 alterations (n = 8), six candidate variants were identified for seven patients. Despite small tumor size, blood-ocular barrier, poor ctDNA blood release and limited plasma sample volumes, we confirm that it is possible to detect ctDNA with high-deep NGS in plasma from patients with intraocular non-hereditary retinoblastoma. This may aid in diagnosis of suspicious cases, family genetic counseling or follow-up of residual intraocular disease.

Identifiants

pubmed: 34298378
pii: S0959-8049(21)00373-7
doi: 10.1016/j.ejca.2021.05.039
pii:
doi:

Substances chimiques

Circulating Tumor DNA 0
RB1 protein, human 0
Retinoblastoma Binding Proteins 0
Ubiquitin-Protein Ligases EC 2.3.2.27

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

277-287

Informations de copyright

Copyright © 2021 Elsevier Ltd. All rights reserved.

Déclaration de conflit d'intérêts

Conflict of interest statement The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Irene Jiménez (I)

SiRIC RTOP « Recherche Translationelle en Oncologie Pédiatrique », Translational Research Department, PSL Research University, Institut Curie Research Center, Paris, France; INSERM U830, Equipe Labellisée Ligue Contre le Cancer, PSL Research University, Institut Curie Research Center, Paris, France; Department of Translational Research, Institut Curie Research Center, Paris, France; SIREDO Center: Care, Innovation and Research for Children, Adolescents and Young Adults with Cancer, Institut Curie, Paris, France.

Éléonore Frouin (É)

Clinical Bioinformatics, PSL Research University, Institut Curie, Paris, France.

Mathieu Chicard (M)

SiRIC RTOP « Recherche Translationelle en Oncologie Pédiatrique », Translational Research Department, PSL Research University, Institut Curie Research Center, Paris, France; INSERM U830, Equipe Labellisée Ligue Contre le Cancer, PSL Research University, Institut Curie Research Center, Paris, France; Department of Translational Research, Institut Curie Research Center, Paris, France; SIREDO Center: Care, Innovation and Research for Children, Adolescents and Young Adults with Cancer, Institut Curie, Paris, France.

Catherine Dehainault (C)

Department of Genetics, PSL Research University, Institut Curie, Paris, France.

Jessica Le Gall (J)

Department of Genetics, PSL Research University, Institut Curie, Paris, France.

Camille Benoist (C)

Clinical Bioinformatics, PSL Research University, Institut Curie, Paris, France.

Arnaud Gauthier (A)

Pathology Department, PSL Research University, Institut Curie, Paris, France.

Eve Lapouble (E)

Somatic Genetics Unit, PSL Research University, Institut Curie, Paris, France.

Claude Houdayer (C)

INSERM U1245, Normandie University, UNIROUEN, Normandy Centre for Genomic and Personalized Medicine and Rouen University Hospital, Department of Genetics, Rouen, France.

François Radvanyi (F)

CNRS, UMR144, Equipe Labellisée Ligue Contre le Cancer, Institut Curie, PSL Research University, Paris, France.

Virginie Bernard (V)

Centre Hospitalier Universitaire Grenoble-Alpes, Grenoble, France.

Hervé J Brisse (HJ)

Imaging Department, PSL Research University, Institut Curie, Paris, France.

Marion Gauthier-Villars (M)

Department of Genetics, PSL Research University, Institut Curie, Paris, France.

Dominique Stoppa-Lyonnet (D)

Department of Genetics, PSL Research University, Institut Curie, Paris, France.

Sylvain Baulande (S)

Institut Curie Genomics of Excellence (ICGex) Platform, PSL Research University, Research Center, Institut Curie, Paris, France.

Nathalie Cassoux (N)

SiRIC RTOP « Recherche Translationelle en Oncologie Pédiatrique », Translational Research Department, PSL Research University, Institut Curie Research Center, Paris, France; SIREDO Center: Care, Innovation and Research for Children, Adolescents and Young Adults with Cancer, Institut Curie, Paris, France; Université de Paris, Paris, France.

Livia Lumbroso (L)

Ocular Oncology Service, Institut Curie, Paris, France.

Alexandre Matet (A)

Ocular Oncology Service, Institut Curie, Paris, France; Université de Paris, Paris, France.

Isabelle Aerts (I)

SIREDO Center: Care, Innovation and Research for Children, Adolescents and Young Adults with Cancer, Institut Curie, Paris, France.

Victor Renault (V)

Clinical Bioinformatics, PSL Research University, Institut Curie, Paris, France.

François Doz (F)

SIREDO Center: Care, Innovation and Research for Children, Adolescents and Young Adults with Cancer, Institut Curie, Paris, France; Université de Paris, Paris, France.

Lisa Golmard (L)

Department of Genetics, PSL Research University, Institut Curie, Paris, France.

Olivier Delattre (O)

INSERM U830, Equipe Labellisée Ligue Contre le Cancer, PSL Research University, Institut Curie Research Center, Paris, France; SIREDO Center: Care, Innovation and Research for Children, Adolescents and Young Adults with Cancer, Institut Curie, Paris, France.

Gudrun Schleiermacher (G)

SiRIC RTOP « Recherche Translationelle en Oncologie Pédiatrique », Translational Research Department, PSL Research University, Institut Curie Research Center, Paris, France; INSERM U830, Equipe Labellisée Ligue Contre le Cancer, PSL Research University, Institut Curie Research Center, Paris, France; Department of Translational Research, Institut Curie Research Center, Paris, France; SIREDO Center: Care, Innovation and Research for Children, Adolescents and Young Adults with Cancer, Institut Curie, Paris, France. Electronic address: gudrun.schleiermacher@curie.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH